Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Hippo-YAP Pathway and Related miRNAs in Preterm Birth (HIPPO-PTB)

8 luglio 2026 aggiornato da: Nazan Yurtcu MD, Cumhuriyet University

Analysis of Hippo-YAP Pathway Genes and Proteins and Related miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375 Expression in Maternal Blood, Placental Tissue, and Myometrial Tissue From Women With Term and Preterm Cesarean Delivery

This completed observational study evaluated the expression of Hippo-YAP pathway-related genes and proteins and selected microRNAs in maternal blood, placental tissue, and myometrial tissue obtained from women who underwent cesarean delivery at term or preterm gestational ages.

The study compared women with spontaneous preterm delivery and women with term delivery. Maternal blood, placental tissue, and myometrial tissue samples were analyzed using molecular, biochemical, and immunohistochemical methods to explore whether Hippo-YAP pathway activity and related miRNA expression patterns may be associated with the pathophysiology of preterm birth.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Preterm birth remains an important obstetric condition associated with neonatal morbidity and mortality. Although clinical risk factors for preterm birth are well described, the underlying molecular mechanisms are not fully understood. Inflammation, immune regulation, placental function, and myometrial activity are considered important components of the biological processes leading to preterm labor and delivery.

The Hippo-YAP signaling pathway is involved in cellular proliferation, differentiation, tissue homeostasis, immune regulation, and placental biology. Several microRNAs are also known to regulate reproductive tissues, placental function, myometrial activity, and inflammatory pathways. Based on this biological background, this study investigated the Hippo-YAP pathway and selected related microRNAs in maternal blood, placental tissue, and myometrial tissue from women with term and preterm cesarean delivery.

This was a completed observational case-control biomarker study. Participants were not assigned to any intervention. The study included two groups: women who delivered preterm and women who delivered at term. Maternal blood samples were collected before cesarean delivery. Placental tissue samples were obtained after delivery, and myometrial tissue samples were collected from the placental bed during cesarean section. Samples were stored under appropriate laboratory conditions until analysis.

The study evaluated the expression of Hippo-YAP pathway-related genes and proteins, including MST1, LATS1, YAP1, TAZ, MAP4K1, and PIK3C2B, as well as selected related microRNAs, including miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375. Gene and microRNA expression analyses were performed using quantitative real-time polymerase chain reaction. Protein expression was assessed using enzyme-linked immunosorbent assay and immunohistochemistry.

The primary objective was to compare Hippo-YAP pathway-related gene, protein, and microRNA expression patterns between preterm and term delivery groups. Secondary objectives included evaluating expression patterns across maternal blood, placental tissue, and myometrial tissue and exploring whether these molecular differences may contribute to understanding the biological mechanisms involved in preterm birth.

The study was approved by the Sivas Cumhuriyet University Clinical Research Ethics Committee. Written informed consent was obtained from participating women. The project was supported by the Scientific and Technological Research Council of Türkiye (TUBITAK), project number 121S414, and the immunohistochemistry experiments were additionally supported by a complementary research grant, project number T-2022-954-D7.

This study was retrospectively registered after completion of participant enrollment, sample collection, and laboratory analyses for transparency.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

44

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Kayseri Ave
      • Sivas, Kayseri Ave, Turchia (Türkiye), 58140
        • Sivas Cumhuriyet University Faculty of Medicine

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Pregnant women who underwent cesarean delivery at Sivas Cumhuriyet University Faculty of Medicine and were included in either the spontaneous preterm delivery group or the term delivery comparison group.

Descrizione

Inclusion Criteria:

- cInclusion Criteria:

  • Pregnant women aged 18 years or older
  • Singleton pregnancy
  • Women who underwent cesarean delivery
  • For the preterm delivery group: spontaneous preterm labor and delivery between 24 and 34 weeks of gestation
  • For the term delivery group: cesarean delivery at term gestational age without active labor
  • Written informed consent for participation and collection of maternal blood, placental tissue, and myometrial tissue samples

Exclusion Criteria:

  • Multiple pregnancy
  • Major fetal anomaly
  • Clinical evidence of chorioamnionitis
  • Hypertensive disorders of pregnancy
  • Diabetes mellitus or gestational diabetes mellitus
  • Autoimmune disease
  • Chronic inflammatory disease
  • Maternal systemic infection
  • Placental abruption
  • Premature rupture of membranes, if excluded in the original protocol
  • Use of medications or presence of maternal conditions that could significantly affect inflammatory, molecular, or placental biomarker expression
  • Refusal to provide informed consent

Exclusion Criteria:

-

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Preterm Delivery Group
Women who underwent cesarean delivery between 24 and 34 weeks of gestation after spontaneous preterm labor. Maternal blood, placental tissue, and myometrial tissue samples were collected for molecular, biochemical, and immunohistochemical analyses.
Laboratory analysis of maternal blood, placental tissue, and myometrial tissue samples for Hippo-YAP pathway-related gene, protein, and microRNA expression. No treatment or clinical intervention was assigned to participants.
Term Delivery Group
Women who underwent cesarean delivery after 39 weeks of gestation without active labor. Maternal blood, placental tissue, and myometrial tissue samples were collected as the term delivery comparison group.
Laboratory analysis of maternal blood, placental tissue, and myometrial tissue samples for Hippo-YAP pathway-related gene, protein, and microRNA expression. No treatment or clinical intervention was assigned to participants.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Expression levels of Hippo-YAP pathway-related genes, proteins, and selected microRNAs
Lasso di tempo: Perioperative/Periprocedural
Expression levels of Hippo-YAP pathway-related genes and proteins, including MST1, LATS1, YAP1, TAZ, MAP4K1, and PIK3C2B, and selected microRNAs, including miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375, were compared between women with preterm delivery and women with term delivery using maternal blood, placental tissue, and myometrial tissue samples.
Perioperative/Periprocedural

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Tissue-specific expression patterns of Hippo-YAP pathway biomarkers and related microRNAs
Lasso di tempo: Perioperative/Periprocedural
Expression patterns of Hippo-YAP pathway-related genes, proteins, and selected microRNAs were evaluated across maternal blood, placental tissue, and myometrial tissue samples to explore tissue-specific molecular differences between preterm and term delivery groups.
Perioperative/Periprocedural

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Nazan Yurtcu, MD, PhD, Cumhuriyet University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 giugno 2021

Completamento primario (Effettivo)

1 aprile 2024

Completamento dello studio (Effettivo)

31 maggio 2024

Date di iscrizione allo studio

Primo inviato

2 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 luglio 2026

Primo Inserito (Effettivo)

10 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TUBITAK-121S414
  • 121S414 (Altro numero di sovvenzione/finanziamento: The Scientific and Technological Research Council of Türkiye (TÜBİTAK), 1002 Rapid Support Program)
  • T-2022-954 (Altro numero di sovvenzione/finanziamento: Sivas Cumhuriyet University BAP)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared because no prospective data-sharing consent for public individual-level data sharing was obtained, and the dataset includes sensitive maternal clinical information and biological sample-related laboratory data.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Laboratory Biomarker Analysis

3
Sottoscrivi